Spinal Muscular Atrophy (SMA) Treatment Market
Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Gene Therapy, Antisense Oligonucleotide Therapy, Small Molecule Therapy), By Route of Administration (Intravenous, Intrathecal, Oral), By Patient Type (Type 1, Type 2, Type 3, Type 4), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies), Forecast Period (2026-2035)
Industry Overview
Spinal Muscular Atrophy (SMA) Treatment Market was valued at $5.8 billion in 2025 and is projected to reach $11.4 billion by 2035, growing at a CAGR of 7.0% from 2026 to 2035. SMA is a rare genetic neuromuscular disorder characterised by progressive muscle wasting due to motor neuron degeneration, driving demand for advanced therapeutics. According to the World Health Organisation (WHO), rare diseases collectively affect over 300 million people globally, with SMA being one of the leading genetic causes of infant mortality. Additionally, regulatory bodies such as the U.S. Food and Drug Administration (FDA) have accelerated approvals for innovative gene therapies, significantly boosting market growth. The market is primarily driven by advancements in gene therapy, increased newborn screening programs, and rising healthcare investments in rare disease treatment. Major end-use sectors include hospitals, speciality clinics, and neurology treatment centres. The increasing adoption of precision medicine and biologics, coupled with strong pipeline developments, is expected to further propel the SMA treatment industry over the forecast period.
Market Dynamics
Rising Adoption of Gene Therapies Driving Market Growth
The rapid adoption of gene therapies is a key driver for the SMA treatment market. Breakthrough therapies targeting the SMN1 gene have transformed disease management, offering long-term clinical benefits with a single-dose treatment approach. According to the U.S. Food and Drug Administration (FDA), gene therapy approvals have significantly increased in the past five years, indicating strong regulatory support. Furthermore, data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights that global R&D investments in biopharmaceuticals exceeded USD 200 billion annually, with a growing share directed toward rare diseases like SMA. Increasing awareness programs and newborn screening initiatives, particularly in developed regions, are improving early diagnosis rates. Pharmaceutical companies are also focusing on strategic collaborations, product expansions, and geographic penetration in 2025–2026. These strategies aim to enhance treatment accessibility and strengthen market presence, particularly in emerging economies.
High Treatment Costs and Limited Accessibility as Key Challenges
Despite promising growth, the SMA treatment market faces challenges due to the high cost of therapies and limited access in low- and middle-income countries. Gene therapies often cost over USD 1 million per treatment, creating affordability concerns for healthcare systems and patients. According to the Organisation for Economic Co-operation and Development (OECD), healthcare expenditure disparities across countries significantly impact access to advanced treatments. Additionally, supply chain complexities associated with biologics and cold-chain logistics further increase operational costs. Another limitation is the lack of widespread reimbursement frameworks and delayed regulatory approvals in certain regions. However, companies are addressing these challenges through value-based pricing models, partnerships with governments, and expansion of manufacturing capabilities to reduce costs and improve availability.
Market Segmentation
- Based on the treatment type, the market is segmented into gene therapy, antisense oligonucleotide therapy, and small molecule therapy.
- Based on the route of administration, the market is segmented into intravenous (IV), intrathecal (spinal injection), and oral.
- Based on the patient type, the market is segmented into type 1 SMA, type 2 SMA, type 3 SMA, and type 4 SMA.
- Based on the distribution channel, the market is segmented into hospital pharmacies, speciality pharmacies, and retail pharmacies.
Gene Therapy Segment Leads the Market
The gene therapy segment dominates the SMA treatment market due to its potential to provide long-term or curative outcomes with a single administration. Increasing adoption of advanced biologics and targeted therapies has driven significant demand in this segment. Between 2022 and 2026, pharmaceutical companies have heavily invested in gene-editing technologies and viral vector-based delivery systems. These innovations improve treatment efficacy and patient outcomes. Additionally, favourable regulatory pathways and orphan drug incentives are accelerating product approvals. Hospitals and speciality treatment centres are increasingly adopting gene therapy due to its clinical effectiveness and reduced long-term treatment burden. This trend is expected to sustain the segment’s leadership throughout the forecast period.
Oral Route of Administration Segment to Record Strong Growth
The oral route of administration is expected to witness the fastest growth due to improved patient compliance and ease of treatment compared to invasive procedures. Oral therapies reduce hospital visits and associated healthcare costs, making them a preferred option for long-term disease management. Technological advancements in small-molecule drug development and RNA-targeting therapies are driving innovation in this segment. Additionally, increasing investments in clinical trials and drug development pipelines are supporting market expansion. Emerging applications in early-stage SMA treatment and maintenance therapy are further contributing to the growth of oral treatments. Pharmaceutical companies are focusing on developing cost-effective and scalable oral formulations to expand their market reach.
Regional Outlook
The global spinal muscular atrophy (SMA) treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America)
North America to Lead the Market
North America leads the SMA treatment market, driven primarily by the United States, where early diagnosis through widespread newborn screening programs and rapid adoption of high-cost therapies such as Zolgensma, Spinraza, and Evrysdi support strong revenue generation. The presence of key players like Biogen and Novartis, along with favourable reimbursement frameworks from private insurers and government programs, ensures high treatment penetration despite premium pricing. Additionally, faster regulatory approvals and strong specialty care infrastructure enable early intervention, particularly for Type I SMA patients, making North America the largest revenue-contributing region.
Europe Region to Record Strong Growth
Europe represents the second-largest market, supported by structured healthcare systems and centralized reimbursement mechanisms across countries such as Germany, France, and the UK. While pricing negotiations and health technology assessments can delay access compared to North America, broad inclusion of SMA therapies in national healthcare coverage ensures steady and sustained uptake of treatments like Evrysdi and Spinraza. Companies such as Roche play a key role in expanding access through country-specific pricing strategies and partnerships. The region also benefits from increasing newborn screening adoption and coordinated rare disease policies, contributing to consistent revenue growth, although at a comparatively moderate pace due to cost-containment measures.
Competitive Landscape
The SMA treatment market is highly competitive, characterized by strong innovation, strategic partnerships, and extensive R&D investments. Companies are focusing on developing next-generation therapies, expanding product portfolios, and strengthening global distribution networks. Key players such as Biogen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, and Cytokinetics are actively involved in advancing treatment options through clinical trials and product innovations. These companies are leveraging gene therapy technologies, RNA-based therapeutics, and precision medicine approaches to maintain a competitive edge. Additionally, collaborations with research institutions and healthcare providers are enabling companies to enhance their supply chain capabilities and improve patient access to treatments worldwide.
Recent Development
- In November 2025, the U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve), a gene therapy developed by Novartis, for the treatment of spinal muscular atrophy (SMA) in both pediatric and adult patients aged 2 years and older with confirmed SMN1 gene mutations. This approval expands the applicability of AAV-based gene therapies beyond early-onset patients, broadening the addressable treated population across multiple disease stages. The therapy leverages adeno-associated virus (AAV) vector technology to deliver a functional copy of the SMN1 gene, targeting the underlying genetic cause of SMA. The decision reflects continued regulatory support for advanced therapies addressing rare diseases and is expected to incrementally increase revenue contribution from gene therapy within the SMA treatment market, particularly by unlocking treatment access for older and previously ineligible patient cohorts.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Spinal Muscular Atrophy (SMA) treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Global Spinal Muscular Atrophy Market Sales Analysis – Treatment Type |
Patient Type | Route of Administration Type | Distribution Channel ($ Million)
• Spinal Muscular Atrophy Market Sales Performance of Top Countries
1.1 Research
Methodology
• Primary Research Approach
• Secondary Research Approach
1.2 Market Snapshot
2. Market Overview
and Insights
2.1 Scope of the Study
2.2 Analyst Insight
& Current Market Trends
??2.2.1 Key Spinal Muscular Atrophy Market Trends
??2.2.2 Market Recommendations
2.3 Porter's Five
Forces Analysis for the Spinal Muscular Atrophy Market
??2.3.1 Competitive Rivalry
??2.3.2 Threat of New Entrants
??2.3.3 Bargaining Power of Suppliers
??2.3.4 Bargaining Power of Buyers
??2.3.5 Threat of Substitutes
3. Market
Determinants
3.1 Market Drivers
??3.1.1 Drivers for Global Spinal Muscular Atrophy Market: Impact Analysis
3.2 Market Pain
Points and Challenges
??3.2.1 Restraints for Global Spinal Muscular Atrophy Market: Impact Analysis
3.3 Market
Opportunities
??3.3.1 Opportunities for Global Spinal Muscular Atrophy Market: Impact
Analysis
4. Competitive
Landscape
4.1 Competitive
Dashboard – Spinal Muscular Atrophy Market Revenue and Share by Manufacturers
• Spinal Muscular Atrophy Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2 Key Company
Analysis
4.2.1 Biogen Inc.
??4.2.1.1 Overview
??4.2.1.2 Product Portfolio
??4.2.1.3 Financial Analysis
??4.2.1.4 SWOT Analysis
??4.2.1.5 Business Strategy
4.2.2 Novartis AG
??4.2.2.1 Overview
??4.2.2.2 Product Portfolio
??4.2.2.3 Financial Analysis
??4.2.2.4 SWOT Analysis
??4.2.2.5 Business Strategy
4.2.3 F.
Hoffmann-La Roche Ltd
??4.2.3.1 Overview
??4.2.3.2 Product Portfolio
??4.2.3.3 Financial Analysis
??4.2.3.4 SWOT Analysis
??4.2.3.5 Business Strategy
4.2.4 Ionis
Pharmaceuticals, Inc.
??4.2.4.1 Overview
??4.2.4.2 Product Portfolio
??4.2.4.3 Financial Analysis
??4.2.4.4 SWOT Analysis
??4.2.4.5 Business Strategy
4.2.5 Cytokinetics,
Inc.
??4.2.5.1 Overview
??4.2.5.2 Product Portfolio
??4.2.5.3 Financial Analysis
??4.2.5.4 SWOT Analysis
??4.2.5.5 Business Strategy
4.3 Top Winning
Strategies by Market Players
??4.3.1
Merger and Acquisition
??4.3.2 Product Launch
??4.3.3 Partnership and Collaboration
5. Global Spinal
Muscular Atrophy Market Sales Analysis by Treatment Type ($ Million)
5.1 Gene Therapy
5.2 Antisense Oligonucleotide Therapy
5.3 Small Molecule Therapy
6. Global Spinal
Muscular Atrophy Market Sales Analysis by Patient Type ($ Million)
6.1 Type 1 SMA
6.2 Type 2 SMA
6.3 Type 3 SMA
6.4 Type 4 SMA
7. Global Spinal
Muscular Atrophy Market Sales Analysis by Route of Administration Type ($
Million)
7.1 Intravenous (IV)
7.2 Intrathecal (Spinal Injection)
7.3 Oral
8. Global Spinal
Muscular Atrophy Market Sales Analysis by Distribution Channel ($ Million)
8.1 Hospital Pharmacies
8.2 Speciality Pharmacies
8.3 Retail Pharmacies
9. Regional
Analysis
9.1 North American
Spinal Muscular Atrophy Market Sales Analysis – Treatment Type | Patient Type |
Route of Administration Type | Distribution Channel | Country ($ Million)
??9.1.1 United States
??9.1.2 Canada
9.2 European Spinal
Muscular Atrophy Market Sales Analysis – Treatment Type | Patient Type | Route
of Administration Type | Distribution Channel| Country ($ Million)
??9.2.1 UK
??9.2.2 Germany
??9.2.3 Italy
??9.2.4 Spain
??9.2.5 France
??9.2.6 Russia
??9.2.7 Rest of Europe
9.3 Asia-Pacific
Spinal Muscular Atrophy Market Sales Analysis – Treatment Type | Patient Type |
Route of Administration Type | Distribution Channel| Country ($ Million)
??9.3.1 China
??9.3.2 Japan
??9.3.3 South Korea
??9.3.4 India
??9.3.5 Australia & New Zealand
??9.3.6 ASEAN Countries
??9.3.7 Rest of Asia-Pacific
9.4 Rest of the
World Spinal Muscular Atrophy Market Sales Analysis – Treatment Type | Patient
Type | Route of Administration Type | Distribution Channel| Country ($ Million)
??9.4.1 Latin America
??9.4.2 Middle East and Africa
10. Company
Profiles
10.1 Alcyone Therapeutics
???10.1.1 Quick Facts
???10.1.2 Company Overview
???10.1.3 Product Portfolio
???10.1.4 Business Strategies
10.2 AndroScience Corporation
???10.2.1 Quick Facts
???10.2.2 Company Overview
???10.2.3 Product Portfolio
???10.2.4 Business Strategies
10.3 Astellas Pharma Inc.
???10.3.1 Quick Facts
???10.3.2 Company Overview
???10.3.3 Product Portfolio
???10.3.4 Business Strategies
10.4 Bayer AG (AskBio)
???10.4.1 Quick Facts
???10.4.2 Company Overview
???10.4.3 Product Portfolio
???10.4.4 Business Strategies
10.5 Biohaven Ltd.
???10.5.1 Quick Facts
???10.5.2 Company Overview
???10.5.3 Product Portfolio
???10.5.4 Business Strategies
10.6 Bio-Path Holdings, Inc.
???10.6.1 Quick Facts
???10.6.2 Company Overview
???10.6.3 Product Portfolio
???10.6.4 Business Strategies
10.7 CANbridge Pharmaceuticals Inc.
???10.7.1 Quick Facts
???10.7.2 Company Overview
???10.7.3 Product Portfolio
???10.7.4 Business Strategies
10.8 Catalyst Pharmaceuticals, Inc.
???10.8.1 Quick Facts
???10.8.2 Company Overview
???10.8.3 Product Portfolio
???10.8.4 Business Strategies
10.9 Eli Lilly and Company (Akouos)
???10.9.1 Quick Facts
???10.9.2 Company Overview
???10.9.3 Product Portfolio
???10.9.4 Business Strategies
10.10 Hanugen Therapeutics
???10.10.1 Quick Facts
???10.10.2 Company Overview
???10.10.3 Product Portfolio
???10.10.4 Business Strategies
10.11 Locanabio, Inc.
???10.11.1 Quick Facts
???10.11.2 Company Overview
???10.11.3 Product Portfolio
???10.11.4 Business Strategies
10.12 NMD Pharma A/S
???10.12.1 Quick Facts
???10.12.2 Company Overview
???10.12.3 Product Portfolio
???10.12.4 Business Strategies
10.13 PepGen Inc.
???10.13.1 Quick Facts
???10.13.2 Company Overview
???10.13.3 Product Portfolio
???10.13.4 Business Strategies
10.14 PTC Therapeutics, Inc.
???10.14.1 Quick Facts
???10.14.2 Company Overview
???10.14.3 Product Portfolio
???10.14.4 Business Strategies
10.15 Regenxbio Inc.
???10.15.1 Quick Facts
???10.15.2 Company Overview
???10.15.3 Product Portfolio
???10.15.4 Business Strategies
10.16 Sarepta Therapeutics, Inc.
???10.16.1 Quick Facts
???10.16.2 Company Overview
???10.16.3 Product Portfolio
???10.16.4 Business Strategies
10.17 Scholar Rock, Inc.
???10.17.1 Quick Facts
???10.17.2 Company Overview
???10.17.3 Product Portfolio
???10.17.4 Business Strategies
10.18 Stoke Therapeutics, Inc.
???10.18.1 Quick Facts
???10.18.2 Company Overview
???10.18.3 Product Portfolio
???10.18.4 Business Strategies
10.19 Taysha Gene Therapies
???10.19.1 Quick Facts
???10.19.2 Company Overview
???10.19.3 Product Portfolio
???10.19.4 Business Strategies
10.20 Voyager Therapeutics, Inc.
???10.20.1 Quick Facts
???10.20.2 Company Overview
???10.20.3 Product Portfolio
???10.20.4 Business Strategies
1. Global Spinal Muscular Atrophy Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
2 Global Gene Therapy Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
3 Global Antisense Oligonucleotide Therapy Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
4 Global Small Molecule Therapy Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
5 Global Spinal Muscular Atrophy Market Research and Analysis by Patient Type, 2025–2035 ($ Million)
6 Global Type 1 SMA Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
7 Global Type 2 SMA Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
8 Global Type 3 SMA Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
9 Global Type 4 SMA Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
10 Global Spinal Muscular Atrophy Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
11 Global Intravenous (IV) Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
12 Global Intrathecal (Spinal Injection) Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
13 Global Oral Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
14 Global Spinal Muscular Atrophy Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
15 Global Hospital Pharmacies Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
16 Global Specialty Pharmacies Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
17 Global Retail Pharmacies Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
18 Global Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
19 North America Spinal Muscular Atrophy Market Research and Analysis by Country, 2025–2035 ($ Million)
20 North America Spinal Muscular Atrophy Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
21 North America Spinal Muscular Atrophy Market Research and Analysis by Patient Type, 2025–2035 ($ Million)
22 North America Spinal Muscular Atrophy Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
23 North America Spinal Muscular Atrophy Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
24 Europe Spinal Muscular Atrophy Market Research and Analysis by Country, 2025–2035 ($ Million)
25 Europe Spinal Muscular Atrophy Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
26 Europe Spinal Muscular Atrophy Market Research and Analysis by Patient Type, 2025–2035 ($ Million)
27 Europe Spinal Muscular Atrophy Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
28 Europe Spinal Muscular Atrophy Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
29 Asia-Pacific Spinal Muscular Atrophy Market Research and Analysis by Country, 2025–2035 ($ Million)
30 Asia-Pacific Spinal Muscular Atrophy Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
31 Asia-Pacific Spinal Muscular Atrophy Market Research and Analysis by Patient Type, 2025–2035 ($ Million)
32 Asia-Pacific Spinal Muscular Atrophy Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
33 Asia-Pacific Spinal Muscular Atrophy Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
34 Rest of the World Spinal Muscular Atrophy Market Research and Analysis by Region, 2025–2035 ($ Million)
35 Rest of the World Spinal Muscular Atrophy Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
36 Rest of the World Spinal Muscular Atrophy Market Research and Analysis by Patient Type, 2025–2035 ($ Million)
37 Rest of the World Spinal Muscular Atrophy Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
38 Rest of the World Spinal Muscular Atrophy Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1 Global Spinal Muscular Atrophy Market Share by Treatment Type, 2025 Vs 2035 (%)
2 Global Gene Therapy Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
3 Global Antisense Oligonucleotide Therapy Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
4 Global Small Molecule Therapy Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
5 Global Spinal Muscular Atrophy Market Share by Patient Type, 2025 Vs 2035 (%)
6 Global Type 1 SMA Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
7 Global Type 2 SMA Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
8 Global Type 3 SMA Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
9 Global Type 4 SMA Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
10 Global Spinal Muscular Atrophy Market Share by Route of Administration, 2025 Vs 2035 (%)
11 Global Intravenous (IV) Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
12 Global Intrathecal (Spinal Injection) Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
13 Global Oral Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
14 Global Spinal Muscular Atrophy Market Share by Distribution Channel, 2025 Vs 2035 (%)
15 Global Hospital Pharmacies Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
16 Global Specialty Pharmacies Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
17 Global Retail Pharmacies Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
18 Global Spinal Muscular Atrophy Market Share by Region, 2025 Vs 2035 (%)
19 United States Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
20 Canada Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
21 UK Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
22 France Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
23 Germany Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
24 Italy Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
25 Spain Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
26 Russia Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
27 India Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
28 China Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
29 Japan Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
30 South Korea Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
31 Australia & New Zealand Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
32 ASEAN Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
33 Rest of Asia-Pacific Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
34 Latin America Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
35 Middle East & Africa Spinal Muscular Atrophy Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
